A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction

References

• Virani SS , AlonsoA, BenjaminEJet al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation, 141(9), e139–e596 (2020).
   PubMed Web of Science ®Google Scholar
• Grundy SM , StoneNJ, BaileyALet al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 73(24), e285–e350 (2018). https://doi.org/10.1161/CIR.0000000000000625
   Google Scholar
• Mach F , BaigentC, CatapanoALet al. ESC/EAS Guidelines for the managementof dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41(1), 111–188 (2020).
   PubMed Web of Science ®Google Scholar
• Pinkosky SL , FilippovS, SrivastavaRAet al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J. Lipid Res., 54(1), 134–151 (2013).
   PubMed Web of Science ®Google Scholar
• Pearce NJ , YatesJW, BerkhoutTAet al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem. J., 334(Pt 1), 113–119 (1998).
   PubMed Web of Science ®Google Scholar
• Agarwala A , GoldbergAC. Bempedoic acid: a promising novel agent for LDL-C lowering. Future Cardiol., 16(5), 361–371 (2020).
   PubMed Web of Science ®Google Scholar
• Esperion Therapeutics INC . Form 10-K - annual report. Commission file number: 001-35986 (2019). https://seekingalpha.com/filing/4849958
   Google Scholar
• Gutierrez MJ , RosenbergNL, MacdougallDEet al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol., 34(3), 676–683 (2014).
   PubMed Web of Science ®Google Scholar
• Thompson PD , RubinoJ, JanikMJet al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J. Clin. Lipidol., 9(3), 295–304 (2015).
   PubMed Web of Science ®Google Scholar
• Thompson PD , MacDougallDE, NewtonRSet al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J. Clin. Lipidol., 10(3), 556–567 (2016).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM , DavidsonMH, MacdougallDEet al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J. Am. Coll. Cardiol., 62(13), 1154–1162 (2013).
   PubMed Web of Science ®Google Scholar
• Esperion Therapeutics . A study of the safety, pharmacokinetic drug interaction and efficacy of ETC-1002 and atorvastatin in subjects with hypercholesterolemia. NCT01779453 (2013). https://www.clinicaltrials.gov/ct2/show/NCT01779453
   Google Scholar
• Esperion Therapeutics . Evaluation of ETC-1002 in patients with hypercholesterolemia and hypertension. NCT02178098 (2015). www.clinicaltrials.gov/ct2/show/NCT02178098
   Google Scholar
• Esperion Therapeutics . Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg when added to PCSK9 inhibitor therapy. NCT03193047 (2018). www.clinicaltrials.gov/ct2/show/NCT03193047
   Google Scholar
• Esperion Therapeutics . Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg triplet therapy in patients with elevated LDL-C. NCT03051100 (2017). www.clinicaltrials.gov/ct2/show/NCT03051100
   Google Scholar
• Lalwani ND , HanselmanJC, MacDougallDE, SterlingLR, CramerCT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. J. Clin. Lipidol., 13(4), 568–579 (2019).
   PubMed Web of Science ®Google Scholar
• Esperion Therapeutics . Assessment of the long-term safety and efficacy of bempedoic acid (CLEAR Harmony OLE). NCT03067441 (2019). www.clinicaltrials.gov/ct2/show/NCT03067441
   Google Scholar
• Esperion Therapeutics . Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) in patients with hyperlipidemia and statin intolerant (CLEAR Serenity). NCT02988115 (2018). www.clinicaltrials.gov/ct2/show/NCT02988115
   Google Scholar
• Ballantyne CM , LaufsU, RayKKet al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur. J. Prev. Cardiol., 27(6), 593–603 (2019).
   PubMed Web of Science ®Google Scholar
• Laufs U , BanachM, ManciniGBJet al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J. Am. Heart Assoc., 8(7), e011662 (2019).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM , BanachM, ManciniGBJet al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis, 277, 195–203 (2018).
   PubMed Web of Science ®Google Scholar
• Ray KK , BaysHE, CatapanoALet al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N. Engl. J. Med., 380(11), 1022–1032 (2019).
   PubMed Web of Science ®Google Scholar
• Goldberg AC , LeiterLA, StroesESGet al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom Randomized Clinical Trial. JAMA, 322(18), 1780–1788 (2019).
   PubMed Web of Science ®Google Scholar
• Lalwani ND , HanselmanJC, MacDougallDE, SterlingLR, CramerCT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. J. Clin. Lipidol., 13(4), 568–579 (2019).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM , LaufsU, RayKKet al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur. J. Prev. Cardiol., 27(6), 593–603 (2020).
   PubMed Web of Science ®Google Scholar
• Banach M , DuellPB, GottoAMet al. Association of bempedoic acid administration with atherogenic lipid levels in Phase III randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol., 5(10), 1–12 (2020).
   Web of Science ®Google Scholar
• Cicero AFG , PontremoliR, FogacciF, ViazziF, BorghiC. Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available Phase II and Phase III clinical studies. Drug Saf., 43(8), 727–736 (2020).
   PubMed Web of Science ®Google Scholar
• Bays HE , BanachM, CatapanoALet al. Bempedoic acid safety analysis: pooled data from four Phase III clinical trials. J. Clin. Lipidol., 14(5), 649–659.e646 (2020).
   PubMed Web of Science ®Google Scholar
• Esperion Therapeutics . Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes). NCT02993406 (2016). www.clinicaltrials.gov/ct2/show/NCT02993406
   Google Scholar
• Esperion Therapeutics . Esperion completes patient enrollment in the Global CLEAR cardiovascular outcomes trial for bempedoic acid. GlobeNewswire. (2019). https://www.globenewswire.com/news-release/2019/09/05/1911428/0/en/Esperion-Completes-Patient-Enrollment-in-the-Global-CLEAR-Cardiovascular-Outcomes-Trial-for-Bempedoic-Acid.html
   Google Scholar
• Raal FJ , KallendD, RayKKet al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N. Engl. J. Med., 382(16), 1520–1530 (2020).
   PubMed Web of Science ®Google Scholar
• Fitzgerald K , Frank-KamenetskyM, Shulga-MorskayaSet al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, Phase I trial. Lancet, 383(9911), 60–68 (2014).
   PubMed Web of Science ®Google Scholar
• Khvorova A . Oligonucleotide therapeutics - a new class of cholesterol-lowering drugs. N. Engl. J. Med., 376(1), 4–7 (2017).
   PubMed Web of Science ®Google Scholar
• Fitzgerald K , KallendD, SimonA. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med., 376(18), e38 (2017).
   PubMedGoogle Scholar
• Wright RS , CollinsMG, StoekenbroekRMet al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin. Proc., 95(1), 77–89 (2020).
   PubMed Web of Science ®Google Scholar
• Ray KK , LandmesserU, LeiterLAet al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med., 376(15), 1430–1440 (2017).
   PubMed Web of Science ®Google Scholar
• Hovingh GK , LeporNE, KallendD, StoekenbroekRM, WijngaardPLJ, RaalFJ. Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 expression in homozygous familial hypercholesterolemia: the ORION-2 pilot study. Circulation, 141(22), 1829–1831 (2020).
   PubMed Web of Science ®Google Scholar
• Ray KK , WrightRS, KallendDet al. Two Phase III trials of inclisiran in patients with elevated LDL cholesterol. N. Engl. J. Med., 382(16), 1507–1519 (2020).
   PubMed Web of Science ®Google Scholar
• University of Oxford . A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). NCT03705234 (2018). www.clinicaltrials.gov/ct2/show/NCT03705234
   Google Scholar
• Novartis Pharmaceuticals . A study of inclisiran in participants with homozygous familial hypercholeterolemia (HoFH) (ORION-5). NCT03851705 (2019). www.clinicaltrials.gov/ct2/show/NCT03851705
   Google Scholar
• Novartis Pharmaceuticals . Novartis receives positive CHMP opinion for leqvio* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol. Novartis News Media Releases (2020). https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-leqvio-inclisiran-potential-first-class-sirna-treatment-high-cholesterol
   Google Scholar
• Saito Y , YokoyamaM, OrigasaHet al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis, 200(1), 135–140 (2008).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , StegPG, MillerMet al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med., 380(1), 11–22 (2019).
   PubMed Web of Science ®Google Scholar
• Bhatt D , MillerM, StegPet al. Achieved eicosapentaenoic acid levels strongly predict cardiovascular benefit in REDUCE-IT. Presented at: ACC’s 69th Annual Scientific Session with WHF’s World Congress of Cardiology (ACC.20/WCC) Virtual Conference (28–30 March 2020).
   Google Scholar
• Budoff M , BrentMuhlestein J, LeVT, MayHT, RoyS, NelsonJR. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: rationale and design of the EVAPORATE study. Clin. Cardiol., 41(1), 13–19 (2018).
   PubMed Web of Science ®Google Scholar
• Budoff MJ , BhattDL, KinningerAet al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur. Heart J., 41(40), 3925–3932 (2020).
   PubMed Web of Science ®Google Scholar
• Das T , KapoorK, BlumenthalR. Results from EVAPORATE trial suggest that cardioprotective benefits of eicosapentaenoic acid (EPA) are related to plaque reduction and stabilization. Expert Analysis. JACC (2020). https://www.acc.org/latest-in-cardiology/articles/2020/09/21/19/13/results-from-evaporate-trial
   Google Scholar
• Nicholls SJ , LincoffAM, GarciaMet al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA, 324(22), 2268–2280 (2020).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN , LeNA, GoldbergIJet al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest., 78(5), 1287–1295 (1986).
   PubMed Web of Science ®Google Scholar
• Crosby J , PelosoGM, AuerPLet al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med., 371(1), 22–31 (2014).
   PubMed Web of Science ®Google Scholar
• Witztum JL , GaudetD, FreedmanSDet al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N. Engl. J. Med., 381(6), 531–542 (2019).
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I , AlexanderV, DigenioAet al. Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial. J. Clin. Lipidol., 11(3), P794–P795 (2017).
   Google Scholar
• Fogacci F , NorataGD, TothPP, ArcaM, CiceroAFG. Efficacy and safety of volanesorsen (ISIS 304801): the evidence from Phase II and III clinical trials. Curr. Atheroscler. Rep., 22(5), 18 (2020).
   PubMed Web of Science ®Google Scholar
• Watts G . RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in plasma triglycerides and LDL-C in human subjects. Presented at: American Heart Association Scientific Sessions,Philadelphia, PA, USA (2019).
   Google Scholar
• Alexander VJ , XiaS, HurhEet al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur. Heart J., 40(33), 2785–2796 (2019).
   PubMed Web of Science ®Google Scholar
• Crooke ST , WitztumJL, BennettCF, BakerBF. RNA-Targeted Therapeutics. Cell Metab., 27(4), 714–739 (2018).
   PubMed Web of Science ®Google Scholar
• Viney NJ , van CapelleveenJC, GearyRSet al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet, 388(10057), 2239–2253 (2016).
   PubMed Web of Science ®Google Scholar
• Tsimikas S , Karwatowska-ProkopczukE, Gouni-BertholdIet al. Lipoprotein(a) reduction in persons with cardiovascular disease. N. Engl. J. Med., 382(3), 244–255 (2020).
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals . Assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with cardiovascular disease (Lp(a) HORIZON). NCT04023552 (2019). www.clinicaltrials.gov/ct2/show/NCT04023552
   Google Scholar
• Amgen . Safety, tolerability, pharmacokinetics and pharmacodynamics study of AMG 890 in subjects with elevated plasma lipoprotein (a). NCT03626662 (2020). www.clinicaltrials.gov/ct2/show/NCT03626662
   Google Scholar
• Melquist S , WakefieldDet al. Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein (a). Circulation, 134, Abstract 17167 (2016).
   Web of Science ®Google Scholar
• Pisciotta L , FavariE, MagnoloLet al. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. Circ. Cardiovasc. Genet., 5(1), 42–50 (2012).
   PubMedGoogle Scholar
• Dewey FE , GusarovaV, DunbarRLet al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N. Engl. J. Med., 377(3), 211–221 (2017).
   PubMed Web of Science ®Google Scholar
• Ahmad Z , BanerjeeP, HamonSet al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation, 140(6), 470–486 (2019).
   PubMed Web of Science ®Google Scholar
• Raal FJ , RosensonRS, ReeskampLFet al. Evinacumab for homozygous familial hypercholesterolemia. N. Engl. J. Med., 383(8), 711–720 (2020).
   PubMed Web of Science ®Google Scholar
• Rosenson RS , BurgessLJ, EbenbichlerCFet al. Evinacumab in patients with refractory hypercholesterolemia. N. Engl. J. Med., 383, 2307–2319 (2020).
   PubMed Web of Science ®Google Scholar
• Graham MJ , LeeRG, BrandtTAet al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N. Engl. J. Med., 377(3), 222–232 (2017).
   PubMed Web of Science ®Google Scholar
• Ballantyne C . RNA interference targeting apolipoprotein C-III results in deep and prolonged reductions in plasma triglycerides. Presented at: American Heart Association Scientific Sessions, Philadelphia, PA, USA (18 November 2019).
   Google Scholar
• Stancu C , SimaA. Statins: mechanism of action and effects. J. Cell. Mol. Med., 5(4), 378–387 (2001).
   PubMed Web of Science ®Google Scholar
• Mihaylova B , EmbersonJ, BlackwellLet al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 380(9841), 581–590 (2012).
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344(8934), 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Ridker PM , MoraS, RoseL, Group JTS. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur. Heart J., 37(17), 1373–1379 (2016).
   PubMed Web of Science ®Google Scholar
• Ridker PM , DanielsonE, FonsecaFAet al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 359(21), 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Phan BA , DayspringTD, TothPP. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag., 8, 415–427 (2012).
   PubMedGoogle Scholar
• Toth PP , DavidsonMH. Cholesterol absorption blockade with ezetimibe. Curr. Drug Targets Cardiovasc. Haematol. Disord., 5(6), 455–462 (2005).
   PubMedGoogle Scholar
• Cannon CP , BlazingMA, GiuglianoRPet al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med., 372(25), 2387–2397 (2015).
   PubMed Web of Science ®Google Scholar
• Sabatine MS , GiuglianoRP, KeechACet al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med., 376(18), 1713–1722 (2017).
   PubMed Web of Science ®Google Scholar
• Schwartz GG , StegPG, SzarekMet al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med., 379(22), 2097–2107 (2018).
   PubMed Web of Science ®Google Scholar
• Cannon CP , CariouB, BlomDet al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur. Heart J., 36(19), 1186–1194 (2015).
   PubMed Web of Science ®Google Scholar
• Gaudet D , KereiakesDJ, McKenneyJMet al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from Phase II trials). Am. J. Cardiol., 114(5), 711–715 (2014).
   PubMed Web of Science ®Google Scholar